These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 22997966

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty (ZDF) rats.
    Togashi Y, Miyamoto Y.
    Exp Toxicol Pathol; 2013 Jul; 65(5):615-22. PubMed ID: 22795897
    [Abstract] [Full Text] [Related]

  • 3. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH.
    Chin Med J (Engl); 2006 May 20; 119(10):814-21. PubMed ID: 16732983
    [Abstract] [Full Text] [Related]

  • 4. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS.
    Exp Clin Endocrinol Diabetes; 2007 Oct 20; 115(9):571-6. PubMed ID: 17943690
    [Abstract] [Full Text] [Related]

  • 5. Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media.
    Rouse RL, Stewart SR, Thompson KL, Zhang J.
    Toxicol Pathol; 2013 Oct 20; 41(4):662-80. PubMed ID: 23085980
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences.
    Pinches M, Betts C, Bickerton S, Burdett L, Thomas H, Derbyshire N, Jones HB, Moores M.
    Toxicol Pathol; 2012 Apr 20; 40(3):522-33. PubMed ID: 22491933
    [Abstract] [Full Text] [Related]

  • 7. Increased aldosterone levels in a model of type 2 diabetes mellitus.
    Fredersdorf S, Endemann DH, Luchner A, Heitzmann D, Ulucan C, Birner C, Schmid P, Stoelcker B, Resch M, Muders F, Riegger GA, Weil J.
    Exp Clin Endocrinol Diabetes; 2009 Jan 20; 117(1):15-20. PubMed ID: 18726873
    [Abstract] [Full Text] [Related]

  • 8. Utility of urinary biomarkers as a diagnostic tool for early diabetic nephropathy in patients with type 2 diabetes mellitus.
    Vijay S, Hamide A, Senthilkumar GP, Mehalingam V.
    Diabetes Metab Syndr; 2018 Sep 20; 12(5):649-652. PubMed ID: 29673928
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit.
    Doi K, Negishi K, Ishizu T, Katagiri D, Fujita T, Matsubara T, Yahagi N, Sugaya T, Noiri E.
    Crit Care Med; 2011 Nov 20; 39(11):2464-9. PubMed ID: 21705884
    [Abstract] [Full Text] [Related]

  • 10. Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes.
    D'Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H.
    Horm Metab Res; 2001 Nov 20; 33(11):664-9. PubMed ID: 11733869
    [Abstract] [Full Text] [Related]

  • 11. Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes.
    Coughlan MT, Forbes JM.
    Am J Nephrol; 2011 Nov 20; 34(1):9-17. PubMed ID: 21654162
    [Abstract] [Full Text] [Related]

  • 12. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
    Nakano R, Kurosaki E, Shimaya A, Kajikawa S, Shibasaki M.
    Eur J Pharmacol; 2006 Nov 07; 549(1-3):185-91. PubMed ID: 16989806
    [Abstract] [Full Text] [Related]

  • 13. Experimental diabetic nephropathy can be prevented by propolis: Effect on metabolic disturbances and renal oxidative parameters.
    Abo-Salem OM, El-Edel RH, Harisa GE, El-Halawany N, Ghonaim MM.
    Pak J Pharm Sci; 2009 Apr 07; 22(2):205-10. PubMed ID: 19339234
    [Abstract] [Full Text] [Related]

  • 14. Protective effect of a poly-phytocompound on early stage nephropathy secondary to experimentally-induced diabetes.
    Marotta F, Harada M, Dallah ED, Yadav H, Solimene U, Di Lembo S, Minelli E, Jain S, Chui DH.
    J Biol Regul Homeost Agents; 2010 Apr 07; 24(1):41-9. PubMed ID: 20385070
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity.
    Hoffmann D, Fuchs TC, Henzler T, Matheis KA, Herget T, Dekant W, Hewitt P, Mally A.
    Toxicology; 2010 Nov 09; 277(1-3):49-58. PubMed ID: 20816719
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.
    Kadian S, Mahadevan N, Balakumar P.
    Eur J Pharmacol; 2013 Jan 05; 698(1-3):388-96. PubMed ID: 23085026
    [Abstract] [Full Text] [Related]

  • 20. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.
    Mima A, Arai H, Matsubara T, Abe H, Nagai K, Tamura Y, Torikoshi K, Araki M, Kanamori H, Takahashi T, Tominaga T, Matsuura M, Iehara N, Fukatsu A, Kita T, Doi T.
    Diabetes; 2008 Jun 05; 57(6):1712-22. PubMed ID: 18285555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.